Exclusive interview for SPINOFF.COM with Moshe Landsberg, CEO of EnzySurge Ltd. on proprietary innovative solution for chronic wounds & burns treatment at wound care
EnzySurge Ltd. was founded in 2001 by Prof. Freeman, a professor of biotechnology and the incumbent Chair in Protein Nanobiotechnology at Tel Aviv University. EnzySurge Ltd. provides proprietary innovative solutions for the global wound care market, in order to promote the natural wound healing process, with focus on outpatient, long-term, and home care settings. It is headquartered in Rosh Ha’ayin, Israel with R&D activities in Israel, clinical activities in USA, India & Israel. EnzySurge Contract Manufacturing Organization is located in Israel.
SOC: Dear Mr. Landsberg, we are so grateful for your generosity this day in spending time speaking with us and sharing your insights about your companies' unique technology and the SilverStream product. We would like to hear more about your vast experience and tremendous job that you have done for the project.
Mr. Landsberg: Good morning, Anastasiia. It is my pleasure to speak with you today and I am thankful for giving me the opportunity to expose EnzySurge and its unique and superior products to more stakeholders. I have an MSc in industrial microbiology from the Hebrew University of Jerusalem. I have an experience of about thirty-nine years in the biopharmaceutical and biotechnological industry, including medical devices, and about 30 of them in different managerial positions such as QA manager, COO, VP technology and CEO, as well as the consultant to most of the Israeli pharmaceutical and biopharmaceutical companies. For the last seven years, I serve as the CEO of EnzySurge Ltd.
SOC: Brilliant, just brilliant experience, thank you and considering such vast experience, we would like also to hear whether you had other projects and could you please share a brief story on their creation and success.
Mr. Landsberg: Well, out of 39 years of experience, 17 years of my professional life I was at BTG Israel and I was a part of the team that developed and later on manufactured ethic drugs: hGH (human growth hormone) and Hyaluronic acid gel for eyes and knees surgeries. I'm also a partner in a patent of the production process of hyaluronic acid in bacteria. In addition, I've served as a consultant to many Israeli companies in pharmaceuticals water systems projects as well as CIP (Cleaning In Place) systems projects and I managed construction of clean rooms project in one of the companies that I worked for. So, I have a vast experience also in consulting for other Israeli companies.
SOC: I see Mr. Landsberg. Thank you so much. If to come back to our current project we would like to hear more about the process of your technology and product later creation. And please tell our investors on which stage of commercialization your project is currently Was it funded by any state financing or grants? Has it already received any honours or awards?
Mr. Landsberg: OK, let's start with our first product which is called SilverStream. The development of SilverStream was started, by the EnzySurge's R&D team, in collaboration with scientists from Tel Aviv University, at the beginning of Q3 of 2008. It took about a year and a half until EnzySurge's R&D team reached the final formulation of SilverStream solution, and the Technical file was submitted to the US-FDA on September 2009 (since SilverStream considered as medical device class II, there wasn't a requirement of clinical trials as part of the submission). On December 2009 the US-FDA cleared SilverStream and permitted its sale in the USA. Consequently, it was approved by the Israeli Ministry of Health, in August 2010.
Case studies in human beings started in Q4, 2010 in St. Vincent Hospital, Erie PA, USA, by Dr.Tomas Serena, one of the well-known KOLs in the USA, and continued, during 2011, in 9 different, well-established hospitals in the north-east of the USA. Four additional series of case studies were done, two of them in three different hospitals in the USA in 2012 and 2013, and two of them in India, during 2013 and 2016, after receiving SilverStream approval from the CDSCO (the Indian FDA) in 2012. A total of about 150 patients were treated successfully in these case studies series.
SilverStream is approved, from 2010, in USA and Israel, from 2012 in India and from 2015 in Kenya, Nigeria and Albania. Until today, more than 30,000 patients were treated successfully with SilverStream, without even one reported adverse event so far. So SilverStream is very safe and very efficient. For SilverStream project there was no state financing or grants.